Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:04:52.448Z.
Consensus retrieved: 2026-10-06T16:52:50.434Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:04:52.448Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e02a3dd73fb38c5e5c6a4c04d5fdd7d1b44dd392d12f2383a7f3aa87a01d004
Forward PE Ratio (N/A) = Dated Quote Price ($10.07) / Consensus Forward EPS ($-0.04)
FORWARD PE RATIO
N/A
Xeris Biopharma Holdings, Inc.
Market Cap
$1.74B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | $1.74B | N/A |
| Absci Corporation (ABSI)vs › | $1.74B | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 46.10 |
| Novocure Ltd (NVCR)vs › | $1.74B | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 32.95 |
| Personalis, Inc. (PSNL)vs › | $1.71B | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 5.59 |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.07, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.04 | $-0.05 – $-0.03 | 4 | n/m |
| 2027-12-31 | $0.36 | $0.13 – $0.52 | 4 | 28.1x |
| 2028-12-31 | $0.58 | $0.35 – $0.87 | 6 | 17.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
